327044-56-4 Usage
Uses
Used in Pharmaceutical Industry:
TERT-BUTYL 6-HYDROXY-3,4-DIHYDROQUINOLINE-1(2H)-CARBOXYLATE is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique structure and reactivity allow for the development of new therapeutic agents with potential applications in treating different diseases and conditions.
Used in Agrochemical Industry:
In the agrochemical industry, TERT-BUTYL 6-HYDROXY-3,4-DIHYDROQUINOLINE-1(2H)-CARBOXYLATE is used as a building block for the creation of new agrochemicals. Its structural properties make it suitable for the development of pesticides, herbicides, and other agricultural chemicals that can improve crop yield and protect plants from pests and diseases.
Used in Materials Science:
TERT-BUTYL 6-HYDROXY-3,4-DIHYDROQUINOLINE-1(2H)-CARBOXYLATE is utilized in materials science for the development of new materials with specific properties. Its reactivity and structural features can contribute to the creation of advanced materials for various applications, such as sensors, catalysts, and other functional materials.
Used in Research and Development:
Due to its potential biological activities, TERT-BUTYL 6-HYDROXY-3,4-DIHYDROQUINOLINE-1(2H)-CARBOXYLATE is used in research and development for exploring its applications in various fields. Scientists and researchers can investigate its interactions with biological systems, which may lead to the discovery of new therapeutic agents, diagnostic tools, or other innovative applications.
Check Digit Verification of cas no
The CAS Registry Mumber 327044-56-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,2,7,0,4 and 4 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 327044-56:
(8*3)+(7*2)+(6*7)+(5*0)+(4*4)+(3*4)+(2*5)+(1*6)=124
124 % 10 = 4
So 327044-56-4 is a valid CAS Registry Number.
327044-56-4Relevant academic research and scientific papers
RENIN INHIBITORS
-
Page/Page column 25; 26, (2009/09/04)
The present invention relates to novel renin inhibitors of general formula (1), novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process of preparing compounds of general formula (1), their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.
Synthesis and SAR of novel histamine H3 receptor antagonists
Jesudason, Cynthia D.,Beavers, Lisa S.,Cramer, Jeffrey W.,Dill, Joelle,Finley, Don R.,Lindsley, Craig W.,Stevens, F. Craig,Gadski, Robert A.,Oldham, Samuel W.,Pickard, R. Todd,Siedem, Christopher S.,Sindelar, Dana K.,Singh, Ajay,Watson, Brian M.,Hipskind, Philip A.
, p. 3415 - 3418 (2007/10/03)
The synthesis and biological evaluation of novel tetrahydroisoquinoline, tetrahydroquinoline, and tetrahydroazepine antagonists of the human and rat H3 receptors are described. The substitution around these rings as well as the nature of the substituent on nitrogen is explored. Several compounds with high affinity and selectivity for the human and rat H3 receptors are reported.
HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATON AND THERAPEUTIC USES
-
Page 17-18, (2010/02/06)
The present invention discloses novel compounds of Formula ( I ) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention disclo
